Search
Abametapir
go.drugbank.com/drugs/DB11932ApprovedThe improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may … [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163]
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
Technetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawnA radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy. … [L1137] The radiopharmaceuticals based on technetium-99m are widely used for diagnostic purposes because 99mTc has a versatile chemistry which allows it to produce an extense variety of complexes with
Levothyroxine
go.drugbank.com/drugs/DB00451ApprovedInvestigational[F4633] T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. … [F4636,A35722] In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T<sub>4</sub>, which is then converted through
Mixtures: L THYROX JOD HEXAL 50/150, L THYROX JOD HEXAL 50/150Categories: UGT1A1 Substrates with a Narrow Therapeutic IndexCarisoprodol
go.drugbank.com/drugs/DB00395Approvedfor abuse in addition to a low risk of dependence [L5074]. … In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential
Synonyms: N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamateNedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalNedaplatin is a second generation platinum analog [A20300]. It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexOxacillin
go.drugbank.com/drugs/DB00713ApprovedInvestigationalAn antibiotic similar to [flucloxacillin] used in resistant staphylococci infections.
International brands: Staficilin-NProducts: OXACILINA 1 G POLVO ESTÉRIL PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, OXACILINA 1G POLVO ESTERIL PARA RECONSTITUIR A SOLUCION INYECTABLE.Benznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. … [L939] It is the first treatment made available in the United States for Chagas disease.
Janssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalThe Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. … A preclinical study in hamsters infected with SARS-COV-2 infection[A220053] showed a single immunization with the vaccine-elicited neutralizing responses and protected against SARS-CoV-2 induced pneumonia
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigational[L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion. … Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).